Rats with chronic heart failure, induced by abdominal aortic binding, were given either growth hormone-releasing peptides, including GHRP-6, or saline water twice a day for three days
Weeks 1-4: 0.25 mg semaglutide + 5-10 mg pyridoxine, injected subcutaneously once weekly Weeks 5-8: 0.5 mg semaglutide + 5-10 mg pyridoxine, injected subcutaneously once weekly Weeks 9-12: 1.0 mg semaglutide + 5-10 mg pyridoxine, injected subcutaneously once weekly Weeks 13-16: 1.7 mg semaglutide + 5-10 mg pyridoxine, injected subcutaneously once weekly Week 17 and beyond: 2.4 mg semaglutide + 5-10 mg pyridoxine, injected subcutaneously once weekly Some providers modify this schedule based on individual tolerance
Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al
Nat Rev Nephrol (2020) 16(9):489508